Commercial Plant-Produced Recombinant Avidin

Hood, Elizabeth E.; Howard, John A.

doi:10.1007/978-3-662-43836-7_2

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings demonstrated that plants can be employed as platforms to produce large-scale recombinant proteins. Over the years, it was demonstrated that plants have the capability to express functionally active proteins from mammals and other eukaryotic organisms with therapeutic activity like human sera, growth factors, vaccines, hormones, cytokines, enzymes and antibodies [127]. This is possible due to the ability of plants to perform the post-translational modifications required for the correct folding of the exogenous proteins in order to keep their functionality and integrity [128,129].…”

Section: Plant Spis: Biotechnology Application In Molecular Farmingmentioning

confidence: 99%

Plant Serine Protease Inhibitors: Biotechnology Application in Agriculture and Molecular Farming

Clemente

Corigliano

Pariani

et al. 2019

IJMS

119

View full text Add to dashboard Cite

The serine protease inhibitors (SPIs) are widely distributed in living organisms like bacteria, fungi, plants, and humans. The main function of SPIs as protease enzymes is to regulate the proteolytic activity. In plants, most of the studies of SPIs have been focused on their physiological role. The initial studies carried out in plants showed that SPIs participate in the regulation of endogenous proteolytic processes, as the regulation of proteases in seeds. Besides, it was observed that SPIs also participate in the regulation of cell death during plant development and senescence. On the other hand, plant SPIs have an important role in plant defense against pests and phytopathogenic microorganisms. In the last 20 years, several transgenic plants over-expressing SPIs have been produced and tested in order to achieve the increase of the resistance against pathogenic insects. Finally, in molecular farming, SPIs have been employed to minimize the proteolysis of recombinant proteins expressed in plants. The present review discusses the potential biotechnological applications of plant SPIs in the agriculture field.

show abstract

Section: Plant Spis: Biotechnology Application In Molecular Farmingmentioning

confidence: 99%

Plant Serine Protease Inhibitors: Biotechnology Application in Agriculture and Molecular Farming

Clemente

Corigliano

Pariani

et al. 2019

IJMS

119

View full text Add to dashboard Cite

show abstract

“…The average yield of avidin in maize was 0.5% of the dry seed weight. A typical egg contains 1.5 mg of avidin, so 800 kg of eggs but only 20 kg of corn would be required to produce 20 g of avidin (69). The yield of E. coli GUS in maize was 80 mg/kg dry seed, and the maize product was identical in size and almost identical in functional parameters (pI, K m , V max , and K i ) to its E. coli counterpart (53).…”

Section: Analytical Applications Of Antibodies Produced By Molecular mentioning

confidence: 99%

Plant Molecular Farming: Much More than Medicines

Tschofen

Knopp

Hood

et al. 2016

Annual Rev. Anal. Chem.

149

103

View full text Add to dashboard Cite

Plants have emerged as commercially relevant production systems for pharmaceutical and nonpharmaceutical products. Currently, the commercially available nonpharmaceutical products outnumber the medical products of plant molecular farming, reflecting the shorter development times and lower regulatory burden of the former. Nonpharmaceutical products benefit more from the low costs and greater scalability of plant production systems without incurring the high costs associated with downstream processing and purification of pharmaceuticals. In this review, we explore the areas where plant-based manufacturing can make the greatest impact, focusing on commercialized products such as antibodies, enzymes, and growth factors that are used as research-grade or diagnostic reagents, cosmetic ingredients, and biosensors or biocatalysts. An outlook is provided on high-volume, lowmargin proteins such as industrial enzymes that can be applied as crude extracts or unprocessed plant tissues in the feed, biofuel, and papermaking industries.

show abstract

“…This was the first plant-made drug approved by major regulators. However, plants have been proposed as a novel paradigm for commercial production of proteins over the next decade (Hood and Howard 2014).…”

Section: Review Articlementioning

confidence: 99%

Potential of plants to produce recombinant protein products

Park

2016

J. Plant Biol.

View full text Add to dashboard Cite

Plants have great potential as photosynthetic factories to produce pharmaceutically important and commercially valuable biomedicines and industrial proteins at low cost. The U.S. Food and Drug Administration (U.S. FDA) has approved the drug Elelyso (taliglucerase alfa) produced by carrot cells for treatment of type 1 Gaucher's disease in 2012. The commercial potential of biomedicines produced by molecular farming has dramatically improved due to the success of an experimental drug called ZMapp, which has immunological activity in Ebola patients. A cocktail of three monoclonal antibodies was produced in tobacco (Nicotiana benthamiana) plants (Chen and Davis 2016). At present, very few drugs made by this technology have been approved by worldwide authorities such as the U.S. FDA. However, plants have been proposed as a novel paradigm for commercial production of proteins over the next decade. In recent years, leading researchers on molecular farming have given more priority to the area of animal-free therapeutic proteins such as parenteral and oral vaccines. Although plant-based platforms have considerable advantages over traditional systems such as bacterial and animal systems, there are several obstacles to commercial-scale production, especially with regards to improving the quality and quantity of plant-produced biologics and industrial materials. One of the biggest barriers to commercialization of this technology is the intense scrutiny of these new plant varieties by regulatory agencies and the public as well as the high costs associated with their regulatory approval.

show abstract

Commercial Plant-Produced Recombinant Avidin

Cited by 5 publications

References 33 publications

Plant Serine Protease Inhibitors: Biotechnology Application in Agriculture and Molecular Farming

Plant Serine Protease Inhibitors: Biotechnology Application in Agriculture and Molecular Farming

Plant Molecular Farming: Much More than Medicines

Potential of plants to produce recombinant protein products

Contact Info

Product

Resources

About